MedTrace Logo

Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

NCT02417662 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-06

No results posted yet for this study

Summary

The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer. Patients will be randomised to receive either standard treatment alone (SACT) or standard treatment with conventional radiotherapy (RT) and SABR.

Conditions

Interventions

RADIATION

Radical Radiotherapy (Conventional RT and SABR)

Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

OTHER

Non-investigational SACT

There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Sponsors & Collaborators

Principal Investigators

  • Fiona McDonald · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-19
Primary Completion
2026-09-30
Completion
2028-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02417662 on ClinicalTrials.gov